Table 1. Characteristics of the 167 Eyes With VF Data Available for Analysis at Baseline by 5-Year VF Testing Completion.
| Characteristic | No. (%) | ||
|---|---|---|---|
| 5-y VF Available | Visit Completed VF Unavailable | Visit Not Completed | |
| No. of eyes | 79 | 40 | 48 |
| Baseline Participant Characteristics | |||
| Female | 40 (51) | 20 (50) | 17 (35) |
| Age, median (IQR), y | 49 (43-56) | 51 (45-56) | 51 (40- 60) |
| Participants with 2 study eyes | 42 (53) | 24 (60) | 24 (50) |
| Race/ethnicity | |||
| Non-Hispanic white | 44 (56) | 24 (60) | 20 (42) |
| Hispanic | 29 (37) | 4 (10) | 13 (27) |
| Non-Hispanic black/African American | 6 (8) | 8 (20) | 12 (25) |
| Othera | 0 | 4 (10) | 3 (6) |
| Diabetes type | |||
| Type 1 | 18 (23) | 9 (23) | 10 (21) |
| Type 2 | 55 (70) | 29 (73) | 38 (79) |
| Uncertain | 6 (8) | 2 (5) | 0 |
| Duration of diabetes, median (IQR), y | 20 (10-24) | 20 (13- 27) | 15 (11-21) |
| Baseline Ocular Characteristics | |||
| Visual acuity letter score | |||
| Mean (SD) | 79 (11) | 77 (10) | 72 (14) |
| Mean Snellen equivalent | 20/32 | 20/32 | 20/40 |
| OCT central subfield thickness, mean (SD), μmb,c | 254 (92) | 255 (99) | 280 (123) |
| Diabetic retinopathy severity (ETDRS level)d | |||
| ≤Mild PDR (level 61) | 22 (28) | 18 (46) | 13(27) |
| Moderate PDR (level 65) | 20 (25) | 13 (33) | 17 (35) |
| High-risk PDR or worse (level 71, 75, 81, or 85) | 37 (47) | 8 (21) | 18 (38) |
| Presence of CI-DME with visual acuity impairmentc,e | 15 (19) | 6 (15) | 19 (40) |
| Prior treatment for DME | 18 (23) | 11 (28) | 11 (23) |
| Prior anti-VEGF for DME | 6 (8) | 2 (5) | 5 (10) |
| Lens status | |||
| Phakic | 73 (92) | 37 (93) | 44 (92) |
| PC IOL | 6 (8) | 3 (8) | 4 (8) |
| Baseline Humphrey VF Testing Data | |||
| HFA 30-2, mean (SD) | |||
| Cumulative score | 2170 (411) | 2220 (365) | 2130 (358) |
| Mean deviation, dB | −5.7 (5.4) | −5.0 (4.4) | −5.7 (4.1) |
| HFA 60-4, mean (SD) | |||
| Cumulative score | 1290 (338) | 1319 (336) | 1150 (397) |
| Mean deviation, dB | −7.8 (5.4) | −7.2 (5.4) | −9.8 (6.1) |
| HFA 30-2 and HFA 60-4 combined, mean (SD) | |||
| Cumulative score | 3460 (726) | 3539 (654) | 3281 (719) |
| Mean deviation, dB | −6.6 (5.2) | -6.0 (4.4) | −7.5 (4.7) |
| 2-y Ocular Characteristics | |||
| Completers | 78 (99) | 40 (100) | 25 (52) |
| Visual acuity letter score | |||
| Mean (SD) | 81 (12) | 82 (15) | 75 (19) |
| Mean Snellen equivalent | 20/25 | 20/25 | 20/32 |
| Development of CI-DME by 2 yc,d,f | 29 (37) | 13 (33) | 25 (53) |
| 5-y Ocular Characteristics | |||
| Completers | 79 (100) | 40 (100) | 0 |
| Visual acuity letter score | |||
| Mean (SD) | 83 (10) | 81 (15) | NA |
| Mean Snellen equivalent | 20/25 | 20/25 | NA |
| Development of CI-DME by 5 yc,e,f | 36 (46) | 15 (38) | 26 (55) |
Abbreviations: anti-VEGF, anti–vascular endothelial growth factor; CI-DME, center-involved diabetic macular edema; DME, diabetic macular edema; ETDRS, Early Treatment Diabetic Retinopathy Study; HFA, Humphrey Field Analyzer; IQR, interquartile range; NA, not applicable; OCT, optical coherence tomography; PC IOL, posterior chamber intraocular lens; PDR, proliferative diabetic retinopathy; VF, visual field.
The Other category included Asian, American Indian/Alaskan Native, more than 1 race, and unknown/not reported.
Assessments from OCT machines other than Zeiss Stratus were converted to equivalent on Zeiss Stratus.5
Baseline OCT central subfield thickness was unavailable for 1 eye that had available 5-year VF and 1 eye that did not complete 5-year visit.
Baseline diabetic retinopathy severity was unavailable for 1 eye that completed the 5-year visit with VF unavailable.
Defined as visual acuity letter scores of ≤78 (20/32 or worse) and presence of CI-DME on OCT (for Heidelberg Spectralis machines, defined as central subfield thickness ≥305 μm for women and ≥320 μm for men; for Zeiss Cirrus and Optovue RTVue machines, defined as central subfield thickness ≥290 μm for women and ≥305 μm for men; for Zeiss Stratus machines, defined as central subfield thickness ≥250 μm) at baseline. Excluding eyes without baseline OCT central subfield thickness.
Defined as presence of CI-DME with vision impairment at baseline or development of CI-DME on OCT with ≥25-μm increase from baseline at any visit during follow-up. Excluding eyes without baseline OCT central subfield thickness.